Nanovi

About Nanovi

Nanovi A/S operates as a medical device company focused on enhancing the precision of cancer treatments through advanced tissue marking technology.

The company was established in December 2012 as a spin-off from the Technical University of Denmark (DTU). Its foundation is built upon a patented biomaterial technology platform, co-invented with DTU's Department of Health Technology, which provides Nanovi with global development and commercial rights. The firm’s journey began with the development of a prototype for its flagship product in 2013 and has since evolved to encompass development, manufacturing, and commercialization. In October 2023, Nanovi and all its assets were acquired by the US-based company CQ Medical, a move intended to support global commercial scaling and a robust market introduction in the United States.

Nanovi generates revenue through the sale of its liquid fiducial markers to healthcare providers, specifically those in the fields of radiation oncology and surgery. Its primary clients are hospitals and cancer treatment centers. The business model centers on providing tools that integrate into existing medical imaging and therapy workflows to improve accuracy. The company's lead product for human use, BioXmark®, is a liquid fiducial marker designed to enhance target visibility on medical imaging for high-precision radiation therapy, including proton therapy. It is administered via injection and transitions into a stable, gel-like marker visible across various imaging modalities like X-ray, CT, MRI, and ultrasound. BioXmark® received its CE marking for the European market in 2020 and was granted De Novo clearance by the U.S. Food and Drug Administration (FDA) in December 2022. The company also commercializes PetXmark™, a version for marking tissue in dogs and cats for veterinary radiotherapy, primarily in the US.

Clinical studies have demonstrated BioXmark®'s positional stability and feasibility for image-guided radiotherapy in treating cancers such as rectal and bladder cancer. These studies confirm the marker is stable, visible on CT-based imaging, and can be injected with minimal adverse events. Following a decade of development, clinical trials, and regulatory approvals, the acquisition by CQ Medical provides the necessary commercial infrastructure to expand the global reach of Nanovi's technology.